Compare ImmunityBio Inc. Common Stock (IBRX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Trip.com Group Ltd — how do they compare? ImmunityBio Inc. Common Stock trades at $10.51 (market cap $10.51B), while Trip.com Group Ltd trades at $38.91 (market cap $23.75B). The key difference: Trip.com Group Ltd is far larger — about 2.3× ImmunityBio Inc. Common Stock's market cap, and Trip.com Group Ltd pays a 0.42% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Trip.com Group Ltd for 79 Days on average.
| IBRX | TCOM | |
|---|---|---|
Market Cap | $10.51B | $23.75B |
Volume | 10,445,785 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $11.55 | $78.96 |
52-Week Low | $1.98 | $37.96 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $10.97B | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Trip.com (TCOM) trades at $38.09, down 0.44% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $1.07, beating expectations by 22%, with revenue growth of 6% year-over-year. Valuation metrics remain attractive with P/E of 7.34 and P/S of 2.6, while maintaining robust profitability with 36.9% net income margin. Recent regulatory changes have introduced competitive pressures, but international travel expansion continues to drive growth.
The stock presents a compelling value opportunity with significant upside to the $56.64 consensus price target, though regulatory headwinds and market volatility pose near-term risks. Strong cash flow generation and debt reduction support the fundamental case, while technical indicators suggest potential for near-term consolidation before upward momentum resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
